Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Study ID
- NCT06653738
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Dietary Exposure
- Kidney Stone
- Nephrolithiasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Empagliflozin 10 MG — DRUGOnce daily per os for 3 years
- Placebo — DRUGOnce daily per os for 3 years
- Personalized dietary counseling — BEHAVIORALPersonalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
- Generic dietary counseling — BEHAVIORALGeneric dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
Study Details
The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones. Study interventions: * Empagliflozin 10 mg once daily per os for 36 months * Personalized dietary counseling for 36 months. Control interventions: * Placebo once daily per os for 36 months * Generic dietary counseling for 36 months.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- May 2026
- Primary completion
- Sep 30, 2030
- Completion
- Sep 30, 2030
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- PREVENTION
Arms
- Experimental: Empagliflozin and personalized dietary counselingEmpagliflozin 10 mg once daily per os and personalized dietary counseling for 3 years
- Placebo Comparator: Placebo and personalized dietary counselingPlacebo once daily per os and personalized dietary counseling for 3 years
- Experimental: Empagliflozin and generic dietary counselingEmpagliflozin 10 mg once daily per os and generic dietary counseling for 3 years
- Placebo Comparator: Placebo and generic dietary counselingPlacebo once daily per os and generic dietary counseling for 3 years
Primary Outcome Measure
Number of patients with radiologic stone recurrence [ Time Frame: After 3 years ]
Central Contacts
- Daniel G Fuster, Prof MD+41 31 632 31 44
Related Studies
- NSAIDs Stent StudyEARLY_PHASE1 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled DietEARLY_PHASE1 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.Recruiting · University of Miami · Miami, Florida
- Oxalate and CitrateRecruiting · University of Chicago · Chicago, Illinois